Table 3.

PURSUIT-Maintenance trial results

PURSUIT-Maintenance	GLM 50 mg every 4 weeks (%)	GLM 100 mg every 4 weeks (%)	Placebo (%)
Continuous clinical response through week 54 (among induction responders)	47	49.7	31.2
Clinical remission at weeks 30 and 54	23.2	27.8	15.6
Mucosal healing at weeks 30 and 54	41.7	42.4	26.6

Notes: The recent Phase IIIPURSUIT clinical trials were the pivotal trials that led to regulatory approval of golimumab for ulcerative colitis.

Abbreviations: GLM, golimumab; PURSUIT, Program of Ulcerative Colitis Research Studies Utilizing an Investigational Treatment.